Table 4.
Cost-effectiveness analysis of IDeg vs. IGlar U100 in type 1 and type 2 diabetes mellitus
| Type 1 diabetes mellitus | Degludec (£) | Glargine U100 (£) | Incremental cost (degludec – glargine U100) (£) |
|---|---|---|---|
| Pharmacy costs (total) | 1339 | 1265 | 73 |
| Insulina | 685 | 611 | 73 |
| Needlesb | 142 | 142 | 0 |
| SMBG testsc | 512 | 512 | 0 |
| Hypoglycaemic events (total) | 189 | 239 | − 51 |
| Nonsevere daytime events | 42 | 42 | 0 |
| Nonsevere nocturnal events | 8 | 10 | − 3 |
| Severe events | 139 | 187 | − 48 |
| Total costs | 1527 | 1505 | 23 |
| Effects | |||
| QALYs | 0.7741 | 0.7509 | 0.0232 |
| ICER (cost per QALY) | 984 | ||
| Type 2 diabetes mellitus | Degludec (£) | Glargine U100 (£) | Incremental cost (degludec – glargine U100) (£) |
|---|---|---|---|
| Pharmacy costs (total) | 1064 | 924 | 140 |
| Insulina | 900 | 760 | 140 |
| Needlesb | 35 | 35 | 0 |
| SMBG testsc | 128 | 128 | 0 |
| Hypoglycaemic events (total) | 28 | 51 | − 23 |
| Nonsevere daytime events | 5 | 6 | − 1 |
| Nonsevere nocturnal events | 4 | 5 | − 1 |
| Severe events | 20 | 40 | − 20 |
| Total costs | 1092 | 975 | 117 |
| Effects | |||
| QALYs | 0.8864 | 0.8798 | 0.0065 |
| ICER (cost per QALY) | 17,939 | ||
Numbers in the table are rounded to the nearest integer for costs and to four decimal places for QALYs
Glargine U100 insulin glargine 100 units/mL, ICER incremental cost-effectiveness ratio, QALYs quality-adjusted life-years, SMBG self-measured blood glucose
aIDeg (in FlexTouch® pen) £46.60 for 1500 units, resulting in cost/unit £0.031; Lantus® (in Solostar® pen) £37.77 for 1500 units, resulting in cost/unit £0.025; insulin aspart (in FlexPen®) £30.60 for 1500 units, resulting in cost/unit £0.020
bBD MicroFine® 5 mm: £9.69 per 100 needles, resulting in a needle price of £0.097
cSMBG test costs of £0.3507 based on the use of one Aviva test strip and one FastClix lancet per test